(NASDAQ: IVVD) Invivyd's forecast annual revenue growth rate of 80.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.93%.
Invivyd's revenue in 2026 is $50,039,000.On average, 6 Wall Street analysts forecast IVVD's revenue for 2026 to be $30,324,618,247, with the lowest IVVD revenue forecast at $14,644,310,186, and the highest IVVD revenue forecast at $64,721,892,403. On average, 6 Wall Street analysts forecast IVVD's revenue for 2027 to be $38,026,996,682, with the lowest IVVD revenue forecast at $12,108,399,998, and the highest IVVD revenue forecast at $87,159,965,176.
In 2028, IVVD is forecast to generate $74,454,770,723 in revenue, with the lowest revenue forecast at $40,437,486,786 and the highest revenue forecast at $110,038,640,105.